Vir Biotechnology (NASDAQ:VIR) CAO Sells $13,627.90 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CAO Brent Sabatini sold 1,430 shares of the business’s stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $9.53, for a total transaction of $13,627.90. Following the transaction, the chief accounting officer owned 69,613 shares in the company, valued at approximately $663,411.89. This trade represents a 2.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Brent Sabatini also recently made the following trade(s):

• On Monday, February 23rd, Brent Sabatini sold 1,829 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.45, for a total transaction of $13,626.05.
• On Friday, February 13th, Brent Sabatini sold 1,530 shares of Vir Biotechnology stock. The stock was sold at an average price of $7.79, for a total transaction of $11,918.70.

Vir Biotechnology Stock Down 2.5%

VIR stock opened at $9.09 on Friday. The firm has a market cap of $1.27 billion, a PE ratio of -2.88 and a beta of 1.69. The business has a 50 day moving average of $7.01 and a 200-day moving average of $6.08. Vir Biotechnology, Inc. has a 12-month low of $4.16 and a 12-month high of $10.94.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings results on Monday, February 23rd. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.11. Vir Biotechnology had a negative return on equity of 49.31% and a negative net margin of 638.88%.The business had revenue of $64.07 million for the quarter, compared to analyst estimates of $19.91 million. During the same period last year, the company posted ($0.76) earnings per share. Vir Biotechnology’s quarterly revenue was up 417.8% compared to the same quarter last year. On average, research analysts expect that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Analyst Ratings Changes

VIR has been the subject of several research reports. Raymond James Financial upgraded shares of Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 price target for the company in a research report on Tuesday. Needham & Company LLC boosted their target price on shares of Vir Biotechnology from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, February 24th. Leerink Partners reissued an “outperform” rating and set a $20.00 target price on shares of Vir Biotechnology in a research report on Thursday. Wall Street Zen upgraded shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Morgan Stanley upped their price objective on Vir Biotechnology from $20.00 to $24.00 and gave the company an “overweight” rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Vir Biotechnology presently has a consensus rating of “Moderate Buy” and an average target price of $19.89.

Hedge Funds Weigh In On Vir Biotechnology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VIR. ARCH Venture Management LLC bought a new stake in shares of Vir Biotechnology in the second quarter valued at approximately $65,100,000. Aberdeen Group plc boosted its holdings in Vir Biotechnology by 51.6% in the 3rd quarter. Aberdeen Group plc now owns 1,526,265 shares of the company’s stock worth $8,715,000 after buying an additional 519,374 shares during the period. Ensign Peak Advisors Inc grew its stake in Vir Biotechnology by 812.7% in the 2nd quarter. Ensign Peak Advisors Inc now owns 582,981 shares of the company’s stock valued at $2,938,000 after buying an additional 519,107 shares in the last quarter. Corton Capital Inc. purchased a new position in Vir Biotechnology in the 2nd quarter valued at approximately $114,000. Finally, Los Angeles Capital Management LLC bought a new stake in Vir Biotechnology during the 2nd quarter valued at $63,000. Institutional investors own 65.32% of the company’s stock.

Vir Biotechnology News Roundup

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas agreed to a collaboration on Vir’s prostate‑cancer asset (VIR‑5500) that includes up‑front and potential milestone payments totaling up to ~$1.7B, materially de‑risking that program and improving commercialization prospects. Read More.
• Positive Sentiment: Q4 results surprised to the upside: EPS and roughly $64M revenue beat consensus, signaling stronger commercial traction and likely underpinning recent analyst optimism. Read More.
• Positive Sentiment: Analysts have raised targets and ratings following the results and deal flow (Needham moved its target to $18), supporting upside from fundamentals despite volatility. Read More.
• Neutral Sentiment: Management will present at TD Cowen and Leerink in early March — useful for additional color and Q&A but not an immediate earnings/cash catalyst. Read More.
• Neutral Sentiment: Increased media/peer comparisons (head‑to‑head coverage) have raised visibility and trading volume; this can amplify moves but doesn’t change Vir’s underlying cashflow or pipeline. Read More.
• Negative Sentiment: Vir priced an underwritten offering of 17,647,058 shares at $8.50 (~$150M gross), which strengthens the balance sheet but is dilutive and increased near‑term share supply — a clear short‑term negative for the stock. Read More.
• Negative Sentiment: Market coverage singled out the discounted offering as the proximate cause of the post‑rally pullback, triggering selling and higher volatility. Read More.
• Negative Sentiment: Multiple insider sales were disclosed last week (including CEO and other senior officers/directors), increasing visible supply and feeding negative sentiment alongside the offering. Individual filings and summaries are available in SEC/insider reports. Read More.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.